Studies have shown that BUBR1 expression is often downregulated in many types of cancer, including colorectal cancer, breast cancer, and lung cancer. This downregulation can be due to genetic mutations, epigenetic modifications, or transcriptional repression. Conversely, overexpression of BUBR1 has also been observed in certain cancers, suggesting a complex role in tumor biology.
